1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

$Thumbnail for Comparative Efficacy and Strategic Sequencing of CAR-T Therapy, Blinatumomab, and Inotuzumab Ozogamicin in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): A Systematic Review and Meta-Analysis$

ALL - 725

Comparative Efficacy and Strategic Sequencing of CAR-T Therapy, Blinatumomab, and Inotuzumab Ozogamicin in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): A Systematic Review and Meta-Analysis

Rajesh Veeramachaneni

Poster Presenter: Rajesh Veeramachaneni

Thumbnail for Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

ALL - 741

Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Kezhi Huang

Poster Presenter: Kezhi Huang

SOHO 2026 Annual Meeting

Posters by Session

Comparative Efficacy and Strategic Sequencing of CAR-T Therapy, Blinatumomab, and Inotuzumab Ozogamicin in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): A Systematic Review and Meta-Analysis

Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Thrombosis-Related Deaths Among Adults With Cancer in the United States, 1999-2024: A 25-Year Analysis

Efficacy of Inotuzumab Ozogamicin When Used As Salvage/Bridging Therapy Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory B-ALL: A Single-Center Experience

The Effect of Obecabtagene autoleucel (obe-cel) on Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) and Extramedullary Disease (EMD)

Levocarnitine and Vitamin B Complex for Prophylaxis Against Pegasparaginase Toxicity in Adults With Acute Lymphoblastic Leukemia

The Role of Blinatumomab in CD19-Positive Precursor B-Cell Acute Lymphoblastic Leukemia Philadelphia-Negative Disease: A 3-Year Update on Progression-Free Survival

Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination with Inotuzumab Ozogamicin and Blinatumomab for Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Prolonged Immune Dysfunction in Survivors of Childhood Hematologic Malignancies